{"id":2147,"date":"2017-05-29T17:39:32","date_gmt":"2017-05-29T12:09:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2147"},"modified":"2025-05-15T14:02:33","modified_gmt":"2025-05-15T08:32:33","slug":"vitiligo-high-unmet-need-indeed","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed","title":{"rendered":"Vitiligo \u2013 High Unmet Need Indeed!"},"content":{"rendered":"<p style=\"text-align: justify;\">Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30. &nbsp;In this condition, patients progressively lose their skin color, mostly in patches. The patches are more visible in people with darker skin. Vitiligo often causes social awkwardness and disturbs the social life of a person.<\/p>\n<p style=\"text-align: justify;\">Instead of worldwide occurrence of this disease, <a href=\"https:\/\/www.delveinsight.com\/report-store\/vitiligo-market\">Vitiligo<\/a> remains one of the most untouched areas in the medical history. There is huge unmet need for this indication as only few treatment options are available for patients with limited efficacy. <a href=\"https:\/\/www.delveinsight.com\/report-store\/vitiligo-epidemiology-forecast\">Vitiligo<\/a> serves as a gateway for other pigemetary disorders.&nbsp; Exploring this indication not only opens more treatment options for Vitiligo, but also leads to better understanding of pigmentary disorders. &nbsp;The exact cause of the disease is still under debate. There are over 30 genes identified to date which might be related to disease onset and development.<\/p>\n<p style=\"text-align: justify;\">In last few years, Researchers and Pharma Players have started focusing on this indication which gives some hope to millions of patients who have been remained unrecognized for years. The driving force behind the increased research activity is the correlation of immune response during melanoma with Vitiligo. Melanoma is the extreme reverse case of the same autoimmune response. The pipeline for <a href=\"https:\/\/www.delveinsight.com\/report-store\/vitiligo-pipeline-insight\">Vitilgo <\/a>is not so strong, with less than 10 products under development. But in coming years, Vitiligo treatment paradigm may take drastic shift due to products which have advanced to clinical studies. Clinuvel Pharmaceuticals and Aclaris Therapeutics are the leaders for this indication with two pipeline products each. Apart from them, many other Pharma companies, researchers from renowned Universities and Institutions such as University of Massachusetts, University of Medicine and Dentistry of New Jersey, University Hospital, Bordeaux etc. are actively exploring this area for potential therapeutic candidates.<\/p>\n<p style=\"text-align: justify;\"><em>Insight by:<\/em><br \/>\n<em>Jyoti Kumari<\/em><br \/>\n<em>Associate Analyst<\/em><\/p>\n<h6 style=\"text-align: justify;\">DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic&nbsp;indications. DelveInsight has a database of 3000+ high-quality analytical <a href=\"https:\/\/www.delveinsight.com\/report-store.php\">reports<\/a>.<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30. &nbsp;In this condition, patients progressively lose their skin color, mostly in patches. The patches are more visible in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2148,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[204,634,381,912,883,911,17526,17527,17528],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-2147","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-delveinsight","tag-drug-development","tag-market-research","tag-melenoma","tag-pipeline-analysis","tag-vitiligo","tag-vitiligo-market","tag-vitiligo-pipeline","tag-vitiligo-therapies","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vitiligo \u2013 High Unmet Need Indeed! - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vitiligo \u2013 High Unmet Need Indeed! - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-29T12:09:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T08:32:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022508\/1-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"662\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vitiligo \u2013 High Unmet Need Indeed! - DelveInsight Business Research","description":"Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed","og_locale":"en_US","og_type":"article","og_title":"Vitiligo \u2013 High Unmet Need Indeed! - DelveInsight Business Research","og_description":"Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age.","og_url":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-05-29T12:09:32+00:00","article_modified_time":"2025-05-15T08:32:33+00:00","og_image":[{"width":1000,"height":662,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022508\/1-4.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed","url":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed","name":"Vitiligo \u2013 High Unmet Need Indeed! - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022508\/1-4.jpg","datePublished":"2017-05-29T12:09:32+00:00","dateModified":"2025-05-15T08:32:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/vitiligo-high-unmet-need-indeed#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022508\/1-4.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022508\/1-4.jpg","width":1000,"height":662},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022508\/1-4-300x199.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">drug development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">melenoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline analysis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vitiligo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vitiligo Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vitiligo Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vitiligo Therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">drug development<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">melenoma<\/span>","<span class=\"advgb-post-tax-term\">Pipeline analysis<\/span>","<span class=\"advgb-post-tax-term\">Vitiligo<\/span>","<span class=\"advgb-post-tax-term\">Vitiligo Market<\/span>","<span class=\"advgb-post-tax-term\">Vitiligo Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Vitiligo Therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on May 29, 2017","modified":"Updated on May 15, 2025"},"absolute_dates_time":{"created":"Posted on May 29, 2017 5:39 pm","modified":"Updated on May 15, 2025 2:02 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2147"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2147\/revisions"}],"predecessor-version":[{"id":32155,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2147\/revisions\/32155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2148"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2147"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2147"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}